Briacell Therapeutics Corp. - Common Shares (BCTX) closed at $3.41 on October 22, 2026, down 5.3% from the previous close, on volume of 61,307 shares (30-day average 108,869).
Data as of October 22, 2026.
BriaCell and BriaPro to Present Four Posters at SITC 2026 Annual Meeting
Globe Newswire (Tue, 6-Oct 7:30 AM ET)
Globe Newswire (Mon, 14-Sep 7:30 AM ET)
Three Nasdaq Cancer Developers Under $10 Advance Clinical Programs
Globe Newswire (Fri, 11-Sep 8:45 AM ET)
BriaCell's Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center
Globe Newswire (Tue, 8-Sep 7:30 AM ET)
Market Chameleon (Mon, 24-Aug 3:47 AM ET)
BriaCell Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+
Globe Newswire (Mon, 24-Aug 7:30 AM ET)
BriaCell Receives FDA Clearance to Initiate Bria-PROS+ Clinical Study in Prostate Cancer
Globe Newswire (Wed, 5-Aug 7:30 AM ET)
Market Chameleon (Wed, 10-Dec 3:18 AM ET)
BriaCell Expands Phase 3 Metastatic Breast Cancer Study With Major New Clinical Sites
Market Chameleon (Tue, 21-Oct 4:25 AM ET)
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.
Briacell Therapeutics Corp. - Common Shares trades on the NASDAQ stock market under the symbol BCTX.
As of October 22, 2026, BCTX stock price declined to $3.41 with 61,307 million shares trading.
BCTX has a beta of 2.29, meaning it tends to be more sensitive to market movements. BCTX has a correlation of 0.09 to the broad based SPY ETF.
BCTX has a market cap of $29.67 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, BCTX traded as high as $895.50 and as low as $2.60.
BCTX has underperformed the market in the last year with a price return of -71.7% while the SPY ETF gained +15.5%. BCTX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -5.3% and -13.0%, respectively, while the SPY returned +2.5% and -1.3%, respectively.
BCTX support price is $3.45 and resistance is $3.76 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BCTX shares will trade within this expected range on the day.
